Association between the ubiquitin carboxyl-terminal esterase l1 gene (UCHL1) S18Y variant and parkinson's disease: A huge review and meta-analysis

American Journal of Epidemiology

Volumn 170, Issue 11, 2009, Pages 1344-1357

  Ragland, Margaret ^a   Hutter, Carolyn ^a   Zabetian, Cyrus ^a,b   Edwards, Karen ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

Case control studies; Epidemiology; Genes; Genetics; Meta analysis; Parkinson disease; Review; UCHL1

Indexed keywords

ANCESTRY; CHROMOSOME; ENZYME ACTIVITY; EPIDEMIOLOGY; GENE EXPRESSION; META-ANALYSIS; NERVOUS SYSTEM DISORDER; RISK FACTOR;

CASE CONTROL STUDY; CAUCASIAN; ENVIRONMENTAL FACTOR; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HUMAN; PARKINSON DISEASE; RACE DIFFERENCE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; UCHL1 GENE;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; HUMANS; MODELS, GENETIC; PARKINSON DISEASE; PREVALENCE; RISK FACTORS; UBIQUITIN THIOLESTERASE;

EID: 70849087363     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp288     Document Type: Review

References (109)

1. Healy DG, Abou-Sleiman PM, Wood NW. Genetic causes of Parkinson's disease: UCHL-1. Cell Tissue Res. 2004;318(1): 189-194.
2. Yu J, Tao Q, Cheung KF, et al. Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. Hepatology. 2008;48(2):508-518.
3. Wilkinson KD, Lee KM, Deshpande S, et al. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science. 1989;246(4930):670- 673.
4. Lowe J, McDermott H, Landon M, et al. Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neu-rodegenerative diseases. J Pathol. 1990;161(2):153-160.
5. Moore DJ, West AB, Dawson VL, et al. Molecular patho-physiology of Parkinson's disease. Annu Rev Neurosci. 2005; 28:57-87.
6. Ciechanover A, Brundin P. The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron. 2003;40(2):427-446.
7. Lim KL, Tan JM. Role of the ubiquitin proteasome system in Parkinson's disease. BMC Biochem. 2007;8(suppl 1):S13.
8. Wing SS. Deubiquitinating enzymes-the importance of driving in reverse along the ubiquitin-proteasome pathway. Int J Biochem Cell Biol. 2003;35(5):590-605.
9. Liu Y, Fallon L, Lashuel HA, et al. The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell. 2002;111(2):209-218.
10. Saigoh K, Wang YL, Suh JG, et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet. 1999;23(1):47-51.
11. Osaka H, Wang YL, Takada K, et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet. 2003;12(16):1945-1958.
12. Meray RK, Lansbury PT Jr. Reversible monoubiquitination regulates the Parkinson disease-associated ubiquitin hydro-lase UCH-L1. J Biol Chem. 2007;282(14):10567-10575.
13. Nazé P, Vuillaume I, Destée A, et al. Mutation analysis and association studies of the ubiquitin carboxy-terminal hydro-lase L1 gene in Huntington's disease. Neurosci Lett. 2002; 328(1):1-4.
14. Ross CA, Pickart CM. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 2004;14(12):703-711.
15. Xue S, Jia J. Genetic association between ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism and sporadic Alzheimer's disease in a Chinese Han population. Brain Res. 2006;1087(1):28-32.
16. Kagara I, Enokida H, Kawakami K, et al. CpG hyper-methylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol. 2008;180(1):343-351.
17. Okochi-Takada E, Nakazawa K, Wakabayashi M, et al. Silencing of the UCHL1 gene in human colorectal and ovarian cancers. Int J Cancer. 2006;119(6):1338-1344.
18. Leroy E, Boyer R, Auburger G, et al. The ubiquitin pathway in Parkinson's disease. Nature. 1998;395(6701):451-452.
19. Nishikawa K, Li H, Kawamura R, et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun. 2003;304(1):176-183.
20. Maraganore DM, Farrer MJ, Hardy JA, et al. Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology. 1999;53(8):1858-1860.
21. Harhangi BS, Farrer MJ, Lincoln S, et al. The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease. Neurosci Lett. 1999;270(1):1-4.
22. Lincoln S, Vaughan J, Wood N, et al. Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hy-drolase gene in familial Parkinson's disease. Neuroreport. 1999;10(2):427-429.
23. Satoh J, Kuroda Y. A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J Neurol Sci. 2001;189(1-2): 113-117.
24. Shi Q, Tao E. An Ile93Met substitution in the UCH-L1 gene is not a disease-causing mutation for idiopathic Parkinson's disease. Chin Med J (Engl). 2003;116(2):312-313.
25. Wintermeyer P, Krüger R, Kuhn W, et al. Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. Neuroreport. 2000;11(10): 2079-2082.
26. Healy DG, Abou-Sleiman PM, Casas JP, et al. UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol. 2006; 59(4):627-633.
27. International HapMap Consortium. The International HapMap Project. Nature. 2003;426(6968):789-796.
28. Carlson CS, Eberle MA, Rieder MJ, et al. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet. 2004;74(1):106-120.
29. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363(9423):1783-1793.
30. Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368-376.
31. Forno LS. Neuropathology of Parkinson's disease. J Neuro-pathol Exp Neurol. 1996;55(3):259-272.
32. Leverenz JB, Umar I, Wang Q, et al. Proteomic identification of novel proteins in cortical Lewy bodies. Brain Pathol. 2007; 17(2):139-145.
33. Spillantini MG, Crowther RA, Jakes R, et al. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 1998;95(11):6469-6473. (Pubitemid 28249037)
34. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114(pt 5): 2283-2301.
35. Hughes AJ, Ben-Shlomo Y, Daniel SE, et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology. 1992;42(6): 1142-1146.
36. Hughes AJ, Daniel SE, Ben-Shlomo Y, et al. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125(pt 4):861-870.
37. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181-184.
38. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology. 2001;57(8):1497-1499.
39. Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism-a prospective study. Can J Neurol Sci. 1991;18(3):275-278.
40. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745-752.
41. Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5): 384-386.
42. Shulman LM, Bhat V. Gender disparities in Parkinson's disease. Expert Rev Neurother. 2006;6(3):407-416.
43. Elbaz A, Bower JH, Maraganore DM, et al. Risk tables for parkinsonism and Parkinson's disease. J Clin Epidemiol. 2002; 55(1):25-31.
44. Hirtz D, Thurman DJ, Gwinn-Hardy K, et al. How common are the "common" neurologic disorders? Neurology. 2007; 68(5):326-337. (Pubitemid 46188246)
45. Elbaz A, Tranchant C. Epidemiologic studies of environmental exposures in Parkinson's disease. J Neurol Sci. 2007; 262(1-2):37-44.
46. von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol. 2005;15(4):473-490.
47. Zhang ZX, Roman GC, Hong Z, et al. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai. Lancet. 2005;365(9459):595-597. (Pubitemid 40247916)
48. Okubadejo NU, Bower JH, Rocca WA, et al. Parkinson's disease in Africa: a systematic review of epidemiologic and genetic studies. Mov Disord. 2006;21(12):2150-2156.
49. Schoenberg BS, Osuntokun BO, Adeuja AO, et al. Comparison of the prevalence of Parkinson's disease in black populations in the rural United States and in rural Nigeria: door-to-door community studies. Neurology. 1988;38(4): 645-646.
50. Albert SM. Projecting neurologic disease burden: difficult but critical. Neurology. 2007;68(5):322-323.
51. Gowers WR. A Manual of the Diseases of the Nervous System. 2nd ed. Philadelphia, PA: Blakiston; 1902.
52. Cummings SR. Understanding Parkinson disease. JAMA. 1999;281(4):276-278.
53. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA. 1999;281(4):341-346. (Pubitemid 29061038)
54. Payami H, Zareparsi S, James D, et al. Familial aggregation of Parkinson disease: a comparative study of early-onset and late-onset disease. Arch Neurol. 2002;59(5):848-850.
55. Foltynie T, Sawcer S, Brayne C, et al. The genetic basis of Parkinson's disease. J Neurol Neurosurg Psychiatry. 2002; 73(4):363-370.
56. Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Hum Mutat. 2007;28(7):641-653.
57. Klein C, Schlossmacher MG. Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder. Neurology. 2007;69(22):2093-2104.
58. Belin AC, Westerlund M. Parkinson's disease: a genetic perspective. FEBS J. 2008;275(7):1377-1383.
59. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009;18(R1):R48-R59.
60. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276(5321):2045-2047.
61. Paisán-Rúiz C, Lang AE, Kawarai T, et al. LRRK2 gene in Parkinson disease: mutation analysis and case control association study. Neurology. 2005;65(5):696-700.
62. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601-607.
63. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998;392(6676):605-608. (Pubitemid 28207717)
64. Bonifati V, Rizzu P, van Baren MJ, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003;299(5604):256-259. (Pubitemid 36131051)
65. Valente EM, Abou-Sleiman PM, Caputo V, et al. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science. 2004;304(5674):1158- 1160.
66. Ramirez A, Heimbach A, Gründemann J, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006;38(10):1184-1191.
67. Gasser T, Müller-Myhsok B, Wszolek ZK, et al. A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet. 1998;18(3):262-265.
68. Hicks AA, Pétursson H, Jónsson T, et al. A susceptibility gene for late-onset idiopathic Parkinson's disease. Ann Neu-rol. 2002;52(5):549-555.
69. Li YJ, Scott WK, Hedges DJ, et al. Age at onset in two common neurodegenerative diseases is genetically controlled. Am J Hum Genet. 2002;70(4):985-993.
70. Pankratz N, Nichols WC, Uniacke SK, et al. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. Hum Mol Genet. 2003;12(20):2599-2608.
71. Sharma M, Mueller JC, Zimprich A, et al. The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations. J Med Genet. 2006;43(7):557-562.
72. Klein C, Lohmann-Hedrich K. Impact of recent genetic findings in Parkinson's disease. Curr Opin Neurol. 2007; 20(4):453-464. (Pubitemid 47051994)
73. Maraganore DM, de Andrade M, Lesnick TG, et al. High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet. 2005;77(5):685-693.
74. Freedman ML, Reich D, Penney KL, et al. Assessing the impact of population stratification on genetic association studies. Nat Genet. 2004;36(4):388-393.
75. Pankratz N, Wilk JB, Latourelle JC, et al. Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet. 2009;124(6):593-605.
76. Evangelou E, Maraganore DM, Ioannidis JP. Meta-analysis in genome-wide association datasets: strategies and application in Parkinson disease [electronic article]. PLoS One. 2007;2(2):e196.
77. Clarimon J, Scholz S, Fung HC, et al. Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. Am J Hum Genet. 2006;78(6):1082-1084; author reply 1092-1094.
78. Farrer MJ, Haugarvoll K, Ross OA, et al. Genomewide association, Parkinson disease, and PARK10. Am J Hum Genet. 2006;78(6):1084-1088; author reply 1092-1094.
79. Goris A, Williams-Gray CH, Foltynie T, et al. No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening. Am J Hum Genet. 2006;78(6):1088-1090.
80. Elbaz A, Nelson LM, Payami H, et al. Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international study. Lancet Neurol. 2006;5(11):917-923.
81. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-535.
82. Hancock DB, Martin ER, Mayhew GM, et al. Pesticide exposure and risk of Parkinson's disease: a family-based case-control study [electronic article]. BMC Neurol. 2008;8:6.
83. Powers KM, Kay DM, Factor SA, et al. Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk. Mov Disord. 2008;23(1):88-95.
84. McCulloch CC, Kay DM, Factor SA, et al. Exploring gene-environment interactions in Parkinson's disease. Hum Genet. 2008;123(3):257-265.
85. Gorell JM, Johnson CC, Rybicki BA, et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology. 1998;50(5):1346-1350.
86. Priyadarshi A, Khuder SA, Schaub EA, et al. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res. 2001;86(2):122-127.
87. Ascherio A, Chen H, Weisskopf MG, et al. Pesticide exposure and risk for Parkinson's disease. Ann Neurol. 2006; 60(2):197-203. (Pubitemid 44182394)
88. Kamel F, Tanner CM, Umbach DM, et al. Pesticide exposure and self-reported Parkinson's disease in the Agricultural Health Study. Am J Epidemiol. 2007;165(4):364-374. (Pubitemid 46254589)
89. Frigerio R, Elbaz A, Sanft KR, et al. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology. 2005;65(10):1575-1583.
90. Shulman LM. Is there a connection between estrogen and Parkinson's disease? Parkinsonism Relat Disord. 2002; 8(5):289-295.
91. Maraganore DM, Lesnick TG, Elbaz A, et al. UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol. 2004; 55(4):512-521.
92. Facheris M, Strain KJ, Lesnick TG, et al. UCHL1 is associated with Parkinson's disease: a case-unaffected sibling and case-unrelated control study. Neurosci Lett. 2005;381(1-2): 131-134.
93. Petitti D. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis: Methods for Quantitative Synthesis in Medicine. New York, NY: Oxford University Press; 1994.
94. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414): 557-560.
95. Hutter CM, Samii A, Factor SA, et al. Lack of evidence for an association between UCHL1 S18Y and Parkinson's disease. Eur J Neurol. 2008;15(2):134-139.
96. Gasser T, Pilz P, Omasmeier D, et al. Ubiquitin C-terminal hydrolase L1 in sporadic Parkinson's disease [abstract]. Mov Disord. 2000:A201.
97. Elbaz A, Levecque C, Clavel J, et al. S18Y polymorphism in the UCH-L1 gene and Parkinson's disease: evidence for an age-dependent relationship. Mov Disord. 2003;18(2):130-137.
98. Wang J, Zhao CY, Si YM, et al. ACT and UCH-L1 polymorphisms in Parkinson's disease and age of onset. Mov Disord. 2002;17(4):767-771.
99. Carmine Belin A, Westerlund M, Bergman O, et al. S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden. Parkinsonism Relat Disord. 2007;13(5):295-298.
100. Mellick GD, Silburn PA. The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson's disease. Neurosci Lett. 2000;293(2):127-130.
101. Levecque C, Destée A, Mouroux V, et al. No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J Neural Transm. 2001;108(8-9):979-984.
102. Savettieri G, De Marco EV, Civitelli D, et al. Lack of asso ciation between ubiquitin carboxy-terminal hydrolase L1 gene polymorphism and PD. Neurology. 2001;57(3):560-561.
103. Maraganore DM, de Andrade M, Lesnick TG, et al. Complex interactions in Parkinson's disease: a two-phased approach. Mov Disord. 2003;18(6):631-636.
104. Ioannidis JP, Boffetta P, Little J, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37(1):120-132.
105. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int. 2007;51(2-4): 105-111.
106. Mizuta I, Satake W, Nakabayashi Y, et al. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet. 2006; 15(7):1151-1158.
107. Momose Y, Murata M, Kobayashi K, et al. Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms. Ann Neurol. 2002; 51(1):133-136.
108. Zhang J, Hattori N, Leroy E, et al. Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkin-sonism Relat Disord. 2000;6(4):195-197. (Pubitemid 30438775)
109. Tan EK, Puong KY, Fook-Chong S, et al. Case-control study of UCHL1 S18Y variant in Parkinson's disease. Mov Disord. 2006;21(10):1765-1768